After introducing intravenous erythropoietin (EPO) as an option for treatment of patients
with indirect traumatic optic neuropathy in 2011 and publishing non inferiority trial in
Oct.2017), TONTT2 is aiming to find out the best dose and timing of EPO administration in
this group of patients.
Phase:
Phase 3
Details
Lead Sponsor:
Iran University of Medical Sciences
Collaborators:
Mashhad University of Medical Sciences Shiraz University of Medical Sciences Tabriz University of Medical Sciences Tehran University of Medical Sciences